Bull flag setting up on this small stock

*Sponsored by Lifewater Media Good morning! It is another wild day in the markets. I hope you are doing ok out there? This is one of those times that I really like being a small-cap trader. It is easy to be nimble and only take trades that make sense to me for as long as they work. It is a slower day than normal out there, with everyone panicking about the SIVB banking issue and also digesting how important today’s job number was. I remember the “old days” when a good job report used to make the markets go up?! On the bright side, I am seeing a lot of great small-cap opportunities in my Lightning Alerts chat room. Over 200 of us are in there looking for fast-moving trades during the day. Before we head into the weekend, I wanted to make sure you don’t forget about CTXR. I still think this is a great idea to keep on your radar. I know it hasn’t made much of a move yet, but this is a great price pattern to watch. I was talking with Jeff about it this morning and he pointed out that CTXR is forming a “bull flag” right now. This is a very tight formation and it could lead to a big move one way or another. Everything is rough right now, but I wouldn’t take your eye off of this one for long. If you look at some of the previous moves that it has had, they have come quickly. I copied the important part of the email I sent out to everyone yesterday, just so you can see it one more time.  What else is worth looking at today? Check this out! Good luck out there today, and I hope you have a great weekend. _______________________________________________ (from yesterday’s email…) A day doesn’t go by that I don’t notice another smaller biotech stock that is making a huge move, and I have never heard of it before. Today, I want to introduce you to one that might not be on your trading radar yet… but it should be! The company is [Citius Pharmaceuticals]( (CTXR) What really got my attention here was a recent press release they issued a few days ago Of course, every company has an annual update, but when I dug into this one I found some exciting information that I don’t think a lot of other people have picked up on yet. Let’s start with the fact that CTXR is sitting on a lot of cash right now. I like a strong balance sheet, and this got my attention right away. In the [press release](, CTXR reported that as of Dec 31, 2022 they had a whopping $36.9 million in cash on hand. CTXR estimates that its available cash resources will be sufficient to fund its operations all the way through February 2024. You can never rule out the need to raise more capital, but right now, it appears to me that CTXR is cashed up for quite a while, which should be great news for shareholders. How many times have you been in a stock that you liked, only to see them issue a lot of new stock to raise more capital? It just happened to me this week on a different stock, and I can tell you it is so frustrating as a trader. I don’t think I have that same type of risk on this stock. Also, management is on the same playing field with investors. From their [website](, you can see that the founders have put in a considerable amount of money.  Over $26 million invested by founders is some real “skin in the game” if you ask me. This would lead me to believe that not only is the management looking to do what is in the best interest of shareholders, but they are going to use their cash very wisely – since so much of their own money is invested! Also looking at their website, you’ll see that the company has what I call “[multiple shots on goal](”. When it comes to a biotech company, we all know that the odds of getting a final FDA approval are hard to come by, but the rewards are great if it happens. When a company has multiple trials running, the odds of at least one trial proving successful goes up. As an investor, I am only looking for just one trial to succeed. If that happens, it is a gamechanger for the company as well as the investors. If you look at the pipeline from CTXR, you will clearly see that there are multiple ways for the company to “win”. And check out this [awesome timeline]( they are projecting for upcoming event catalysts for what they have in the pipeline… Getting to a “Phase III” trial is quite an achievement.  If you have traded biotech stocks, then you know most of them die at the “Phase II” stage. CTXR, however, reported an uptick in patient recruitment for their Mino-Lok Phase 3 trial.  CTXR was also granted “Fast Track” designation by the FDA Their I/ONTAK compound has even received orphan drug designation by the FDA. Since it is in such an advanced phase, I think this is the “shot on goal” I am most interested in and looks like they will have a crucial event later this year. CTXR also reported in the press release above that their Halo-Lido Phase 2b trial nearing completion. I can’t speculate on the odds of this being successful, but it is… that would be HUGE for the company. That would give them two catalysts in Phase III trials.  This will be exciting to keep an eye on because it looks like this announcement will be coming up soon from the timeline they showed above. From a [technical trading perspective](, you have to like where the stock is at right now. CTXR stock is just trading barely above $1, which has been a crucial line in the sand for support / resistance in the past, and you also have some critical announcements coming up soon. If any one of those announcements turns out to be positive, then I think it would completely change the outlook for CTXR. I am really excited to see what happens with this company over the next few months. There is so much potential around the corner! In summary, I think the company sums up the opportunity here very well. I just copied this from their website: CTXR is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a diversified pipeline of five active programs. Three of its pipeline candidates would be the first and only prescription treatments in their indications if approved by the FDA. The Company has two late-stage product candidates and one product in Phase 2 clinical development. All in all, this is an [amazing opportunity]( to look into. I really encourage you to do your own research on CTXR, and understand more about the risks and potential upside possibilities. Get started by checking everything out on their [website](. I hope you have a great day of trading. Good luck! *Please see disclosures below Jason Bond RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Manage your email subscriptions.]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. If you have a current active subscription with Jason Bond Picks you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at JasonBondPicks.com. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.